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Abstract
Background:During the last decade, the prevalence of carbapenem-
resistant infection associated with multidrug resistant (MDR) Acineto-
bacter baumanniiin patients has been continuously increasing. This 
prospective study aimed to determine the occurrence and molecu-
lar characterization of metallo-β-lactamases (MBLs) and carbapenem 
hydrolyzing oxacillinases among A. baumannii isolates from cancer 
patients over a period of 6-month.
Methods:Antimicrobial susceptibility profile of 70 randomly collected 
A. baumannii isolates was first determined using disc diffusion test, 
and second, the MICs of 45 representative multidrug resistant (MDR) 
isolates were tested to most clinically used drugs in treatment of their 
infections using E-test. PCR assays were used to detect the common 
four types of class D carbapenem hydrolyzing oxacillinases, two types 
of class A carbapenemases, four types of class B metallo-β –lactama-
ses, and prevalence of Class 1 Integron among MDR isolates. 
Results:All 70 isolates were MDR, including 100% resistance to me-
ropenem, aztreonam, piperacillin/tazobactum and 99% to carbape-
nem. All isolates carried blaOXA-23 and blaOXA-51, but none carried 
a blaOXA-24 like or blaOXA-58. The isolates were also positive for 
NDM-1, VIM, GES, KPC and SPM at the rates of 29%, 20%, 29%, 
19%, 7% and 2%, respectively. Class 1 Integron was positive in 82% 
of A. baumannii isolates. 
The clonal relationship of 42 MDR A. baumannii isolates using ERIC-
PCR and constructed dendrogram showed 3 major genotype clusters 
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of genetically related isolates. These include 4 genotype groups, each 
composed of 2 isolates with 100% similarity of DNA bands. 
Conclusion:This study demonstrates that A. baumannii colonize fre-
quently cancer patients in association with antibiotic treatment. The 
organism is mostly carrying wide spectrum of antibiotic resistance 
genetic factors, especially many types of ESBLs and MBLs and Class 
1 Integron. This fact should be considered when therapy is selected 
for treatment of patients infected with MDR A. baumannii. 
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Introduction
In recent years worldwide including Jordan, most 
clinical A. baumannii isolates have developed re-
sistant to most clinically used drugs, and caused 
increased morbidity and mortality among hospita-
lized patients in intensive care units (ICUs) [1-4].
Acinetobacter spp. develop multidrug resistance 
through mechanism of mutation in penicillin-bin-
ding proteins (PBPs), alterations in outer membra-
ne proteins (OMPs) and increased activity of eff-
lux pumps [5]. However, resistance to β- lactams 
appears to be primarily caused by production of 
β- lactamases which include extended-spectrum-
β-lactamases (ESBLs), oxacillinases, and metallo-β-
lactamases [6].
A. baumannii acts first often as colonizer rather 
than a pathogen because of its wide distribution 
and colonizing capability [1, 7], especially in immu-
ne-compromised and among patients with prolon-
ged hospital stay [8]. The spectrum of infections 
caused by this pathogen include ventilator-asso-
ciated pneumonia (VAP) which is developed after 
prolonged hospitalization or mechanical ventilation 
and prior use of antibiotics [4, 9-10].
Many factors contribute to the ability of A. bau-
mannii to cause infections in hospitalized patients. 
First, A. baumannii has the capacity to survive for 
long periods in various body parts of patients and 
their environment. Secondly, the genomic makeup 
of this organism allows it to acquire resistance to 
many antibiotics within a short period [11]. Howe-
ver, the rates of antibiotic resistance vary from re-
gion to region and among hospitals [12]. Almost all 
studies indicate that MDR A. baumannii infections 
are difficult to treat, spread quickly among hospi-
talized patients and can be associated with high 
mortality due to blood sepsis or ventilator associa-
ted pneumonia [2, 4, 12-14]. 
This study describes the occurrence and the me-
chanism of antibiotic resistance of A. baumannii 
isolated from cancer patients. 
Patients and Methods
Collection of A. baumannii isolates 
This prospective study included a total of 70 A. 
baumannii isolates, were recovered from clinical 
specimens of patients who were investigated for 
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presence of A. baumannii during hospitalization or 
investigation as outpatients at a Cancer Center in 
Amman, Jordan, over a period of 6-months (2016) 
as shown in the Table 2. Approval was obtained 
from the Institution Ethical Review Board (IERB) at 
the King Hussein Cancer Center (KHCC), Amman, 
Jordan, for conducting and publishing this study. 
Identification of A. baumannii isolates
All isolateswere first identified using BioMerieux VI-
TEK 2 Automated Microbiology System (France). La-
ter all collected isolates were sub-cultured on Blood 
and MacConkey agar plates and incubated at 37°C 
for 24 hr. Pure growth was again confirmed as A. 
baumannii according to the following characteris-
tics; negative oxidase test, negative lactose and glu-
cose fermentation in Kligler iron tubes, and later by 
presence of OXA-51 gene using PCR. Five fresh co-
lonies were inoculated in brain-heart infusion agar 
plus 15% glycerol and kept frozen at -70 ºC until 
used for further investigation. 
Antibiotic susceptibility tests
The susceptibility of A. baumannii isolates to an-
tibiotics was determined using the disc diffusion 
method according to the guidelines of CLSI 2016 
[15]. The minimum inhibitory concentrations (MICs) 
of isolates were determined by the E-test (ABBioMé-
rieux, France) for imipenem, amikacin and colistin. 
Interpretations of the MICs in the E-test were done 
according to the guidelines of CLSI 2016 [15].
Genomic DNA Extraction from A. 
baumannii Isolates
Genomic DNA was extracted according to the 
manufacturer’s instructions of Wizard Genomic 
DNA purification kit (Promega, USA). 
Plasmid DNA extraction from A. 
baumannii isolates
The bacterial plasmid was extracted using the EZ-10 
Spin Column Plasmid DNA Minipreps Bio Basic kit 
(Canada) according to manufactures protocol.
Detection of genes encoding blaOXA 
carbapenemases, metalo-beta-lactamases, 
and class-1 integron in A. baumannii using 
PCR
All primer target genes of blaOXA carbapenemases, 
metalo-beta-Lactamases, their sequences, product 
sizes, annealing temperatures were used according 
to references as shown in Table 1. β-lactamases ge-
nes (OXA-58, OXA-51, OXA-24, OXA-23 [16], IMP-
2, VIM-2, SPM, NDM, [17], GES [18], NDM-1(19)KPC 
[20] and class-1integron [21].
The following control strains were used in the 
experiment, which were kindly donated by Prof. 
Monzer Hamza, Laboratoire Microbiologie Sante et 
Environnement (LMSE), Ecole Doctorale des Scien-
ces et de Technologie, Faculte de Sante Publique, 
Universite Libanaise, Tripoli, Lebanon):A. baumannii 
(OXA-51 positive), A. baumannii (OXA-23 positi-
ve), A. baumannii (IMP-2 positive), K. pneumonia 
(blaKPC positive; ATCC BAA-1705), K. pneumonia 
(blaNDM-1positive; ATCC BAA-2146), and P. aerugi-
nosa (ATCC 2 7853) was used in susceptibility test.
PCR tests were carried out in 25 μl reaction with 
2.5 μl of extracted DNA, 20 pmol of each primer 
(Alpha DNA, Montreal, Canada), 12.5 μl GoTaq® 
Green master mix (Promega, USA). The volume was 
made up to 25 µl using nuclease free water. DNA 
concentrations of each sample was evaluated using 
Nanodrop 2000c (Thermo scientific, USA). The 
PCR amplification assays for the target genes were 
performed using programmable PCR-Thermocycler 
(Bioerxp cycler, China). Control tubes containing 
master mix without template DNA were included 
in each run as negative control. Tubes were held 
at 4°C when the cycles were ended. The amplified 
products and the PCR DNA marker were separated 
via electrophoresis on 2% agarose gels containing 
15% Red safe™ stain (5 µl), for 40-50 min at 120 
volts, and then visualized using Gel documentation 
system including:UV camera, monitor and printer 
(UVP, USA).
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Table 1.  Primers of blaOXA - carbapenemases, Metalo-beta-Lactamases ,Class-1 integrons, ERIC.
Gene targets  Primer Sequence (5'→3') Annealing Temp.oC Product size (bp) Reference
blaOXA-51 
F→TAATGCTTTGATCGGCCTTG
R→TGGATTGCACTTCATCTTGG
60 353
16
blaOXA-23 
F→GATCGGATTGGAGAACCAGA
R→ATTTCTGACCGCATT TCCAT 
57 501
blaOXA-24 
F→GGTTAGTTGGCCCCCTTAAA
R→AGTTGAGCGAAAAGGGGATT 
57 246
blaOXA-58- 
F→AAGTATTGGGGCTTGTGCTG
R→CCCCTCTGCGCTCTACATAC 
57 599
IMP
F→GGA ATA GAG TGG CTT AAY TCTC
R→GGT TTA AYA AAA CAA CCA CC
52 232 
17
VIM
F→GAT GGT GTT TGG TCG CAT A
R→CGA ATG CGC AGC ACC AG
52 390 
SPM
F→AAA ATC TGG GTA CGC AAA CG
R→5'- ACA TTA TCC GCT GGA ACA GG
52 271
NDM
F→GGT TTG GCG ATC TGG TTT TC
R→CGG AAT GGC TCA TCA CGATC
52 621 
GES
F→ATG CGC TTC ATT CAC GCA C
R→CTA TTT GTC CGT GCT CAG GA
56 863 18
NDM-1
F→ATT AGC CGC TGC ATT GAT
R→CAT GTC GAG ATA GGA AGT G
58 154 19
KPC
F- GATACCACGTTCCGTCTGG
R- GCAGGTTCCGGTTTTGTCTC
52 246 20
intI1
intI1
F→ACATGTGATGGCGACGCACGA
R→ATTTCTGTCCTGGCTGGCGA
55 600 21
ERIC-1
ERIC-2
ATGTAAGCTCCTGGGGATTCACAAG
TAAGTGACTGGGGTGAGCG 
52 Multiple Bands 22 
Enterobacterial repetitive consensus 
(ERIC)-PCR
This test was performed in 50 μl volumes contai-
ning 10 ng of genomic DNA from A. baumannii 
clinical isolates, 4 mM MgCl2, 50 pM each of pri-
mer ERIC-1 and 2 as described by Jeong et al. [22].
Statistical analysis 
Statistical analysis was done using SPSS version 20, 
chi square test and t-test were used to analyzed 
categorical variablesand to measure the significance 
of the association between the study variables. If 
less than 5 a fisher exact test was used. P-value of 
≤ 0.05 was considered significant \.
Results
Table 2 Shows the sources of 70 A. baumannii iso-
lates within the period of study (March 2016 to 
October 2016). The majority of samples were co-
llected from nasal swabs (30%) and perianal swabs 
(21%). Table 3 shows the demographic characteris-
tics of cancer patients with positive A. baumannii 
isolates. The majority of patients (56%) were over 
50 years old and were in-patient (90%) rather than 
out-patient (10%). Most of the patients (68%) have 
received medication prior to collection their spe-
cimens. The results of antimicrobial susceptibility 
using disc diffusion method are presented in Ta-
ble 4 A. baumannii isolates were 100% resistant 
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Table 2.  Sources, number and percent of collected 
samples from patients.
Source
Samples*
No %
Nasal swab NS) 21 30
Perianal swab PS) 15 21
TRAP 8 11
Wound swab WS) 8 11
Blood 4 6
Urine 5 7
High vaginal Swab HVS) 3 4
Sputum 2 3
Broncho alveolar lavage BAL) 2 3
Throat 1 1.5
Pleural fluid 1 1.5
Pleural fluid 1 1.5
*: Only one sample was included from each patient.
Table 3. Demographic characteristics of 70 cancer patients with positive A. baumannii isolates.
Patients characteristics
Hospitalized patients Out-patients Total
P-Value
No % No % No %
Skills
Males 38 54 1 1 39 55
0.026**Females 25 36 6 9 31 45
Total 63 90 7 10 70 100
Age /year
Less than 14 2 3 0 0 2 3 0.601
15-50 26 37 2 3 28 40
0.667More than 50 34 49 5 7 39 56
Total 63 90 7 10 70 100
Prior use of antibiotic
No antibiotic 18 26 4 6 22 32
0.033**Treatment with antibiotics* 45 64 3 4 48 68
Total 63 90 7 10 3
*: Mostly amikacin and colistin. **: Significant
to meropenem, piperacillin/tazobactum, aztreonam 
and ceftazidime, 99% resistant to imipenem, and 
ciprofloxacin, 76%, 77% resistant to amikacin and 
gentamycin, respectively. The results of MICs for the 
three commonly used drugs amikacin, colisitn and 
imipenem against A. baumannii isolates are shown 
in Table 4.
A total of 45 A. baumannii isolates were 100% 
positive to OXA23 like and OXA51, and all of these 
were negative to OXA58 like and OXA24 genes. 
Table 5 shows the distribution of other potential 
genes of VIM, GES, NDM-1, NDM, IMPa, KPC, and 
SPM werefound in 64%, 42%, 29, 20%, 7%, 7%, 
2%, respectively, while integron-1 was presented in 
83% of the isolates.
The genetic relationship of 42 MDR A. baumannii 
isolates from hospitalized patients as shown in the 
dendrogram indicated 3 major genotype clusters of 
genetically related isolates (Figure 1). These include 
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Table 4.  Antimicrobial resistance patterns of 70 A. 
baumannii isolates using disc diffusion and 
E-tests for MICs.
Antimicrobial 
agent
resistant 
isolates
 MIC50 MIC90 
MIC-
range 
No %  mg/L  mg/L mg/L
Meropenem 
(Mem) 70 100  - - -
aztreonam (Atm) 70 100  - - -
Piperacillin/
Tazobactum (Ptz)
70 100  - - -
Ceftazidime (Caz) 70 100  - - -
Ciprofloxacin 
(Cip)
69 99  - - -
Imipenem (IMI) 69 99 15.6 28.5 0.38-32
Gentamicin (GM) 54 77 - - -
Amikacin (Ak) 53 76 98.3 177 1-256
Colistin - 0.26 0.47 0.019-2
Table 5.  Distribution of bla OXA-carbapenemases, 
MBLs and Integron-1 genes among 45 A. 
baumannii isolates.
Gene name
Positive isolates
No %
OXA-23 45 100
OXA-24 0
OXA-51 45 100
OXA-58 0
VIM 29 64
GES 19 42
NDM-1 13 29
NDM 9 20
IMP 3 7
KPC 3 7
SPM 1 2
Integron-1 37 82
Figure 1:  Dendrogram of the 42 A. baumannii isolates from hospitalized patients.
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4 genotype groups, each composed of 2 isolates 
with 100% similarity of DNA bands. 
The identity of class-1 integron PCR products of 
5 A. baumannii isolates were confirmed by sending 
them to Macrogen Inc. (Seoul, Korea) for sequen-
cing and the results were analyzed using alignment 
search tool of Blast. (http://www.ncbi.nlm.nih.gov/
BLAST) and the multiple sequence alignment pro-
gram, CLUSTALW (http://www.ebi.ac.uk/clustalw).
Discussion
This study has demonstrates that many body sites 
of cancer patients are frequently colonized with A. 
baumannii, especially their nares andperianal site. 
Invasive blood infection was detected among few 
percentage (6%)of hospitalized cancer patients du-
ring the 6-month study period (Table 2).The rest of 
the isolates can be considered colonizers and might 
become potential pathogens for patients under cer-
tain condition, especially in association with the use 
of invasive procedures [23-24]. There is no signifi-
cance difference in general demographic characte-
ristics between male and female patients or their 
ages, whereas treatment with antibiotics showed 
increased significantly the chance of (P=0.033) co-
lonization with A. baumanni. Additionally, hospita-
lized patients were at increased risk for colonization 
with AB (90%; P=0.026) when compared to out-
patients (10%) with A. baumannii (Table 3). Recent 
studies from Jordan and other countries reported 
that A. Baumannii frequently colonizes hospitalized 
patients, causing sporadic invasive infection and 
nosocomial outbreaks, especially among critically ill 
patients and in ICUs [2, 25-27].
This study demonstrates that the majority of A. 
baumannii species isolates were resistant in the 
range between 76% to 100% to commonly useful 
antimicrobial agents in the treatment of gram-ne-
gative infections, including infections due to A. bau-
mannii (Table 4). Previous studies which has been 
performed over the last few years at the Jordan 
University Hospital and KHCC in Amman, have also 
found that the majority of A. baumannii isolates 
from patients and hospital environment sources was 
also multidrug resistant [2, 3, 28].
The ability to acquire resistance to a broad range 
of antimicrobial agents within a short period and 
during treatment is commonly observed in A. bau-
mannii [4, 29]. High mortality rates among critically 
ill patients infected with MDRor extensively drug-
resistant (XDR) A. baumannii strains (resistant to all 
antibiotics except colistin and tigecycline, have been 
recently described in many regions [30-32]. 
This study shows extremely high rate of carba-
penems-resistance (99-100%) among A. bauman-
nii isolates. The prevalence of imipenem-resistance 
among A. baumannii isolates was 99%. This rate 
is very high compared to resistance rates of clinical 
isolates reported few years ago from Jordan and 
neighboring countries which ranged between 90% 
to 64% [3, 31, 32, 33]. A previous Jordanian study 
has also indicated that majority of Abaumannii iso-
lates from environmental and clinical sources was 
multidrug resistant, except for colistin and tigecycli-
ne similar to the case in other countries such as 
Lebanon [3, 32]. 
Carbapenems are frequently used as the drugs 
of choice in treatment of infections caused by MDR 
Gram-negative bacteria including A. baumannii. In-
creased resistance to carbapenems in A. baumannii 
has raised special concerns during the last decade, 
especially since it is associated mostly with the pro-
duction of acquired carbapenemases belonging to 
either carbapenem-hydrolyzing OXA-type class D 
-β-lactamases or class B metallo-β-lactamases [32, 
35-36]. The results of this study demonstrate that all 
representative examined 45 MDR A. baumannii iso-
lates were 100% positive for genes of blaOXA-51, 
and blaOXA-23, but none of the isolates was po-
sitive to OXA-24 or OXA-58. A recent Jordanian 
study carried at the Jordan University Hospital also 
showed that all examined A. baumannii isolates 
harbored a blaOXA-51gene, 58% has a blaOXA-
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23gene, and 38.8% has a blaOXA-24 gene [3]. It 
is well known that blaOXA-51 gene, is an enzyme 
that naturally exists in A. baumannii and has very 
weak carbapenem hydrolyzing activity [37].Whi-
le the presence of plasmid-borne blaOXA-23 and 
blaOXA-58 genes have been shown to contribute 
significantly to carbapenem resistance in A. bau-
mannii worldwide [38]. However, the distribution of 
carbapenem-hydrolyzing oxacillinases varies among 
regions and hospitals [3, 32-35, 38]. A study used 
multivariate analysis demonstrated that the risk fac-
tors for acquisition of MDR A. baumannii were not 
related specifically to presence of cancer, but rather 
due to exposure of patients to health care proce-
dures, especially dialysis, antibiotic treatment and 
length of stay in intensive care unities [4, 7]. 
The present study also demonstrates that all A. 
baumannii isolates were susceptible to colistin. This 
result is similar to most recent studies from neighbo-
ring countries which has reported high susceptibility 
rates of clinical A. baumannii isolates to colistin [2-
3, 25, 32, 35]. However, with an increase of using 
colistin to treat carbapenem-resistant A. baumannii 
infections, colistin resistance could be later emerged 
[39].
This study revealed that 37 of the 45 (82%) MDR 
A. baumannii isolates harbored class-1 Integrons 
(Table 5). Previous studies from Jordan has demons-
trated that class 1- integrons is frequently found in 
clinical and environmental isolates of Gram-negative 
bacteria such as A. baumannii and E. coli and are of-
ten associated with their MDR strains [28, 40]. The 
presence of the integrase gene in the majority of 
our A. baumannii clinical isolates in association with 
other resistance markers provided a strong evidence 
that these isolates have the potential for acquisition 
more antimicrobial resistance genes in future. It has 
been often observed that MDR A. baumannii strains 
involved in hospital outbreaks have carried class 1 
integrons [41-42].
The ERIC-PCR analysis as shown by dendrogram 
demonstrated that few A. baumannii isolates might 
have been circulated among cancer patients (Figure 
1). Further testing of these isolates using multilocus 
sequence typing (MLST) or DNA sequencing could 
confirm this result. 
In conclusion, the results of this study demons-
trate that body colonization with A. baumannii in-
creased in association with antibiotic treatment of 
cancer patients. The majority of A. baumannii are 
carrying a wide spectrum of genetic resistance fac-
tors, especially many important types of blaOXA-
carbapnemases which will limit using valuable drugs 
in treatment of A. baumannii invasive infection. 
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